CN106491914A - 一种治疗烫伤的西药组合物 - Google Patents
一种治疗烫伤的西药组合物 Download PDFInfo
- Publication number
- CN106491914A CN106491914A CN201611101764.5A CN201611101764A CN106491914A CN 106491914 A CN106491914 A CN 106491914A CN 201611101764 A CN201611101764 A CN 201611101764A CN 106491914 A CN106491914 A CN 106491914A
- Authority
- CN
- China
- Prior art keywords
- parts
- western medicine
- medicine compound
- scald
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010053615 Thermal burn Diseases 0.000 title claims abstract description 55
- 150000001875 compounds Chemical class 0.000 title claims abstract description 51
- 239000003814 drug Substances 0.000 title claims abstract description 51
- 238000011282 treatment Methods 0.000 claims abstract description 42
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims abstract description 36
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims abstract description 19
- 235000012907 honey Nutrition 0.000 claims abstract description 19
- 229960001727 tretinoin Drugs 0.000 claims abstract description 19
- 235000019484 Rapeseed oil Nutrition 0.000 claims abstract description 18
- 229960003276 erythromycin Drugs 0.000 claims abstract description 18
- 229930002330 retinoic acid Natural products 0.000 claims abstract description 18
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 claims abstract description 17
- 229960000785 fluocinonide Drugs 0.000 claims abstract description 17
- 238000002347 injection Methods 0.000 claims abstract description 15
- 239000007924 injection Substances 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 239000009692 xuesetong Substances 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960002509 miconazole Drugs 0.000 claims abstract description 13
- 229960003088 loratadine Drugs 0.000 claims abstract description 12
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims description 25
- 235000011837 pasties Nutrition 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 14
- 239000004927 clay Substances 0.000 claims description 8
- 239000012467 final product Substances 0.000 claims description 7
- 239000011812 mixed powder Substances 0.000 claims description 7
- 238000003801 milling Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 231100000241 scar Toxicity 0.000 abstract description 20
- 230000001139 anti-pruritic effect Effects 0.000 abstract description 9
- 239000003908 antipruritic agent Substances 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 7
- 230000008961 swelling Effects 0.000 abstract description 6
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 238000013329 compounding Methods 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000035876 healing Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 22
- 206010052428 Wound Diseases 0.000 description 18
- 208000027418 Wounds and injury Diseases 0.000 description 18
- 206010037660 Pyrexia Diseases 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 150000003851 azoles Chemical class 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000256113 Culicidae Species 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 208000002506 Darier Disease Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010023369 Keratosis follicular Diseases 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 206010027146 Melanoderma Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 201000010618 Tinea cruris Diseases 0.000 description 1
- 206010052568 Urticaria chronic Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000027993 eye symptom Diseases 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000004607 keratosis follicularis Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 208000027406 nose symptom Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 239000010499 rapseed oil Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Insects & Arthropods (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗烫伤的西药组合物,包括以下重量分数的原料:醋酸氟轻松10‑20份、氯雷他定片10‑20份、维a酸1‑5份、血塞通5‑8份、红霉素5‑8份、去痛片1‑3份、蜂蜜10‑15份、芦荟胶1‑3份、咪康唑2‑5份、菜籽油5‑10份。该西药组合物通过原料复配发挥协同作用,可以有效治疗各种烫伤,可以及时对烫伤皮肤进行止痒、去痛、消肿,且对于烫伤疤痕的修复也有很好的疗效,且患者治愈后无复发,是一种安全有效的西药组合物;该西药组合物的制备方法简单,原料易得,生产成本较低;另外,该西药组合物还具有使用方法简单、无毒副作用的优点。
Description
技术领域
本发明涉及西药技术领域,具体是一种治疗烫伤的西药组合物。
背景技术
烫伤(scald)是由无火焰的高温液体(沸水、热油、钢水)、高温固体(烧热的金属等)或高温蒸气等所致的组织损伤。常见低热烫伤,低热烫伤又可称为低温烫伤。是因为皮肤长时间接触高于体温的低热物体而造成的烫伤。接触70℃的温度持续1分钟,皮肤可能就会被烫伤;而当皮肤接触近60℃的温度持续5分钟以上时,也有可能造成烫伤,这种烫伤就叫做低温烫伤。
由于低热烫伤常发生在人体下肢。一般情况下,皮肤与低温热源短时间接触,仅造成真皮浅层的水疱型烫伤,但如果低温热源持续作用,就会逐渐发展为真皮深层及皮下各层组织烫伤。低温烫伤和高温引起的烫伤不同,创面疼痛感不十分明显,仅在皮肤上出现红肿、水疱、脱皮或者发白的现象,面积也不大,烫伤皮肤表面看上去烫伤不太严重,但创面深严重者甚至会造成深部组织坏死,如果处理不当,严重会发生溃烂,长时间都无法愈合。烫伤的严重程度主要根据烫伤的部位、面积大小和烫伤的深浅度来判断。
烫伤的程度,一般分为三度:一度伤、二度伤、三度伤。一度伤是指烫伤只损伤皮肤表层,局部轻度红肿、无水疱、疼痛明显,一度伤治疗时,应立即脱去衣袜后,将无破损创面放入冷水中浸洗半小时,再用麻油、菜油涂擦创面;二度伤是指烫伤是真皮损伤,局部红肿疼痛,有大小不等的水疱,二度伤治疗时,大水疱可用消毒针刺破水疱边缘放水,涂上烫伤膏后包扎,松紧要适度;三度伤是指烫伤是皮下,脂肪、肌肉、骨骼都有损伤,并呈灰或红褐色,三度伤治疗时,应用干净布包住创面及时送往医院。上述烫伤治疗方法存在周期长、见效慢的缺点,不能及时减轻人们的痛苦,而且容易发生感染,影响身体恢复。
发明内容
本发明的目的在于提供一种治疗烫伤的西药组合物,以解决上述背景技术中提出的问题。
为实现上述目的,本发明提供如下技术方案:
一种治疗烫伤的西药组合物,包括以下重量分数的原料:醋酸氟轻松10-20份、氯雷他定片10-20份、维a酸1-5份、血塞通5-8份、红霉素5-8份、去痛片1-3份、蜂蜜10-15份、芦荟胶1-3份、咪康唑2-5份、菜籽油5-10份。
作为本发明进一步的方案:包括以下重量分数的原料:醋酸氟轻松15份、氯雷他定片13份、维a酸2份、血塞通6份、红霉素7份、去痛片2份、蜂蜜13份、芦荟胶2份、咪康唑3份、菜籽油8份。
一种治疗烫伤的西药组合物的制备方法,具体步骤为:(1)首先将氯雷他定片、血塞通、去痛片研磨成粉末后混合,得到混合粉末A;(2)将醋酸氟轻松、维a酸、红霉素和咪康唑混合后得到膏状物质;(4)将上述膏状物质在40-60℃温度下干燥20-50min,然后磨成粉末B;(5)将粉末A和粉末B混合均匀,然后放入菜籽油中炸30-50s;(6)将油炸后的粉末与蜂蜜、芦荟胶混合,并搅拌均匀,即得膏状西药组合物。
作为本发明再进一步的方案:所述步骤(1)血塞通在研磨前先将糖衣去除。
作为本发明再进一步的方案:所述步骤(4)将上述膏状物质在50℃温度下干燥35min,然后磨成粉末B。
作为本发明再进一步的方案:所述步骤(5)将粉末A和粉末B混合均匀,然后放入菜籽油中炸45s。
与现有技术相比,本发明的有益效果是:
该西药组合物通过原料复配发挥协同作用,可以有效治疗各种烫伤,可以及时对烫伤皮肤进行止痒、去痛、消肿,且对于烫伤疤痕的修复也有很好的疗效,且患者治愈后无复发,是一种安全有效的西药组合物;该西药组合物的制备方法简单,原料易得,生产成本较低,有利于市场推广;另外,该西药组合物还具有使用方法简单、使用效果好的优点,且外涂使用,无毒副作用。
具体实施方式
下面结合具体实施方式对本专利的技术方案作进一步详细地说明。
实施例1
一种治疗烫伤的西药组合物,包括以下重量分数的原料:醋酸氟轻松10份、氯雷他定片10份、维a酸1份、血塞通5份、红霉素5份、去痛片1份、蜂蜜10份、芦荟胶1份、咪康唑2份、菜籽油5份。
一种治疗烫伤的西药组合物的制备方法,具体步骤为:(1)首先将氯雷他定片、血塞通、去痛片研磨成粉末后混合,得到混合粉末A;(2)将醋酸氟轻松、维a酸、红霉素和咪康唑混合后得到膏状物质;(4)将上述膏状物质在40℃温度下干燥20min,然后磨成粉末B;(5)将粉末A和粉末B混合均匀,然后放入菜籽油中炸30s;(6)将油炸后的粉末与蜂蜜、芦荟胶混合,并搅拌均匀,即得膏状西药组合物。
实施例2
一种治疗烫伤的西药组合物,包括以下重量分数的原料:醋酸氟轻松20份、氯雷他定片20份、维a酸5份、血塞通8份、红霉素8份、去痛片3份、蜂蜜15份、芦荟胶3份、咪康唑5份、菜籽油10份。
一种治疗烫伤的西药组合物的制备方法,具体步骤为:(1)首先将氯雷他定片、血塞通、去痛片研磨成粉末后混合,得到混合粉末A;(2)将醋酸氟轻松、维a酸、红霉素和咪康唑混合后得到膏状物质;(4)将上述膏状物质在60℃温度下干燥50min,然后磨成粉末B;(5)将粉末A和粉末B混合均匀,然后放入菜籽油中炸50s;(6)将油炸后的粉末与蜂蜜、芦荟胶混合,并搅拌均匀,即得膏状西药组合物。
实施例3
一种治疗烫伤的西药组合物,包括以下重量分数的原料:醋酸氟轻松15份、氯雷他定片13份、维a酸2份、血塞通6份、红霉素7份、去痛片2份、蜂蜜13份、芦荟胶2份、咪康唑3份、菜籽油8份。
一种治疗烫伤的西药组合物的制备方法,具体步骤为:(1)首先将氯雷他定片、血塞通、去痛片研磨成粉末后混合,血塞通在研磨前先将糖衣去除,得到混合粉末A;(2)将醋酸氟轻松、维a酸、红霉素和咪康唑混合后得到膏状物质;(4)将上述膏状物质在50℃温度下干燥35min,然后磨成粉末B;(5)将粉末A和粉末B混合均匀,然后放入菜籽油中炸45s;(6)将油炸后的粉末与蜂蜜、芦荟胶混合,并搅拌均匀,即得膏状西药组合物。
实施例4
一种治疗烫伤的西药组合物,包括以下重量分数的原料:醋酸氟轻松12份、氯雷他定片12份、维a酸2份、血塞通6份、红霉素6份、去痛片1.5份、蜂蜜11份、芦荟胶1.6份、咪康唑2.8份、菜籽油6.5份。
一种治疗烫伤的西药组合物的制备方法,具体步骤为:(1)首先将氯雷他定片、血塞通、去痛片研磨成粉末后混合,得到混合粉末A;(2)将醋酸氟轻松、维a酸、红霉素和咪康唑混合后得到膏状物质;(4)将上述膏状物质在50℃温度下干燥25min,然后磨成粉末B;(5)将粉末A和粉末B混合均匀,然后放入菜籽油中炸35s;(6)将油炸后的粉末与蜂蜜、芦荟胶混合,并搅拌均匀,即得膏状西药组合物。
实施例5
一种治疗烫伤的西药组合物,包括以下重量分数的原料:醋酸氟轻松19份、氯雷他定片18份、维a酸4.5份、血塞通7.2份、红霉素6.5份、去痛片2.3份、蜂蜜14份、芦荟胶2.5份、咪康唑3.4份、菜籽油9份。
一种治疗烫伤的西药组合物的制备方法,具体步骤为:(1)首先将氯雷他定片、血塞通、去痛片研磨成粉末后混合,得到混合粉末A;(2)将醋酸氟轻松、维a酸、红霉素和咪康唑混合后得到膏状物质;(4)将上述膏状物质在55℃温度下干燥46min,然后磨成粉末B;(5)将粉末A和粉末B混合均匀,然后放入菜籽油中炸45s;(6)将油炸后的粉末与蜂蜜、芦荟胶混合,并搅拌均匀,即得膏状西药组合物。
本发明的理论基础:
醋酸氟轻松:外用适用于对糖皮质激素有效的皮肤病,如接触性皮炎、特应性皮炎、脂溢性皮炎、湿疹、皮肤瘙痒症、银屑病、神经性皮炎等瘙痒性及非感染性炎症性皮肤病。其疗效显著而副作用较小,局部涂敷对皮肤、黏膜的炎症、瘙痒及皮肤过敏反应等均有效。显效迅速,止痒效果好。应用很低浓度(0.025%),即有明显疗效。止痒作用较好。
氯雷他定片:用于缓解过敏性鼻炎有关的症状,如喷嚏、流涕、鼻痒、鼻塞以及眼部痒及烧灼感。口服药物后,鼻和眼部症状及体征得以迅速缓解。亦适用于缓解慢性荨麻疹、瘙痒性皮肤病及其他过敏性皮肤病的症状及体征。
维a酸:维A酸是体内维生素A的代谢中间产物,主要影响骨的生长和促进上皮细胞增生、分化、角质溶解等代谢作用。用于治疗寻常痤疮、银屑病、鱼鳞病、扁平苔癣、毛发红糠疹、毛囊角化病、鳞状细胞癌及黑色素瘤等疾病。
血塞通:本品能扩张冠脉和外周血管、降低外周阻力、减慢心率、减少和降低心肌耗氧量、增加心肌灌注量、增加脑血流量、对心肌和脑缺血有一定改善作用;具显著抑制血小板凝聚、降低血液粘稠度、抑制血栓形成的作用;此外,本品还具降血脂,抗疲劳,耐缺氧,提高和增强巨噬细胞功能等作用。
红霉素:抗菌谱与青霉素近似,对革兰阳性菌,如葡萄球菌、化脓性链球菌、绿色链球菌、肺炎链球菌、粪链球菌、梭状芽孢杆菌、白喉杆菌等有较强的抑制作用。对革兰阴性菌,如淋球菌、螺旋杆菌、百日咳杆菌、布氏杆菌、军团菌、以及流感嗜血杆菌、拟杆菌也有相当的抑制作用。此外,对支原体、放线菌、螺旋体、立克次体、衣原体、奴卡菌、少数分枝杆菌和阿米巴原虫有抑制作用。
去痛片:用于发热及轻、中度的疼痛。
蜂蜜:蜂蜜含有其他多种人体不可或缺的微量元素,是天然的美容保健品。
芦荟胶:芦荟胶是以"冷冻稳定法"技术从天然草本植物"芦荟"中萃取而成,其纯度非常高,无毒副作用,对割伤、擦伤、伤口溃烂、烫伤、皮肤痕痒、青春痘、黑斑、蚊虫叮咬、牙痛、唇角溃烂、手术疤痕等等都有明显的辅助作用,使用安全可靠。
咪康唑:用于皮肤真菌感染,如手、足、体、股癣。
菜籽油:可润燥杀虫、散火丹、消肿毒。
该西药组合物治疗烫伤的疗效观察:
本发明临床选用烫伤患者300例,其中男155例,女145例;本发明临床选用患者200例,一度伤患者120例、二度伤患者100例、三度伤患者80例;其中男145例,女155例。
应用方法:患者每日涂抹本发明实施例3制备的西药组合物,一日涂抹3次,早、中、晚各涂抹一次,一次保持10分钟,3天为一个疗程。
烫伤的疗效标准:显效、有效和无效。
(1)显效:一度伤患者和二度伤患者涂抹1个疗程后,烫伤部位皮肤止痒、去痛、消肿,发烧患者退热,且皮肤恢复光滑,一个月内无复发;三度伤患者伤口涂抹1个疗程后,烫伤部位皮肤止痒、去痛、消肿,发烧患者退热,涂抹3个疗程后,烫伤部位恢复,皮肤恢复光滑,无疤痕,一个月内无复发。
(2)有效:一度伤患者和二度伤患者涂抹1个疗程后,烫伤部位皮肤止痒、去痛、消肿,发烧患者退热,且皮肤恢复光滑,一个月内无复发;三度伤患者伤口涂抹1个疗程后,烫伤部位皮肤止痒、去痛、消肿,发烧患者退热,涂抹5个疗程后,烫伤部位恢复,皮肤恢复光滑,无疤痕,一个月内无复发。
(3)无效:涂抹1个疗程后,烫伤部位无止痒、去痛、消肿效果,且患者恢复后,皮肤有疤痕。
治疗结果见表1:
表1西药组合物治疗烫伤疗效
项目 | 患者人数/人 | 显效人数/人 | 有效人数/人 | 无效人数/人 | 有效率/% |
一度伤 | 120 | 80 | 40 | 0 | 100 |
二度伤 | 100 | 95 | 5 | 0 | 100 |
三度伤 | 80 | 40 | 35 | 5 | 93.8 |
结果表明本发明的西药组合物可以治疗各种类型的烫伤,一度伤和二度伤有效率可达100%,三度伤有效率可达93.8%,治疗效果显著,是一种安全有效的西药组合物。
修复烫伤疤痕的疗效观察:
本发明临床选用疤痕患者200例,均为烧伤后留下的疤痕。将患者分为两组,即治疗组和对照组,每组100例。
应用方法:对照组每日涂抹其他外用软膏,按说明书使用;治疗组每日涂抹本发明实施例3制备的西药组合物,一日4次,一次保持30分钟后清洗,10天为一个疗程。
修复疤痕疗效标准:显效,有效和无效。
(1)显效:治疗2个疗程后,疤痕处皮肤润泽,无凹陷、突起,无疤痕印迹,停止治疗后一个月,无复发。
(2)有效:治疗3个疗程后,疤痕处皮肤润泽,凹陷凸起部位不明显,疤痕处皮肤色泽接近周围正常皮肤,治疗4个疗程后,疤痕症状完全消失,停止治疗后一个月,无复发。
(3)无效:治疗3个疗程后,疤痕质地有好转,但停止治疗后症状复原。
治疗结果见表2:
表2西药组合物治疗烫伤疤痕疗效
组别 | 病例数 | 显效例数 | 有效例数 | 无效例数 | 总有效率 |
对照组 | 100 | 40 | 20 | 40 | 60% |
治疗组 | 100 | 85 | 14 | 1 | 99% |
由上表可以看出,该西药组合物治疗烫伤疤痕有效率可达99%,比对照组高39%,且停药后把整症状无复发,是一种安全有效的治疗烫伤疤痕的西药组合物。
该西药组合物通过原料复配发挥协同作用,可以有效治疗各种烫伤,可以及时对烫伤皮肤进行止痒、去痛、消肿,且对于烫伤疤痕的修复也有很好的疗效,且患者治愈后无复发,是一种安全有效的西药组合物;该西药组合物的制备方法简单,原料易得,生产成本较低,有利于市场推广;另外,该西药组合物还具有使用方法简单、使用效果好的优点,且外涂使用,无毒副作用。
上面对本专利的较佳实施方式作了详细说明,但是本专利并不限于上述实施方式,在本领域的普通技术人员所具备的知识范围内,还可以在不脱离本专利宗旨的前提下做出各种变化。
Claims (6)
1.一种治疗烫伤的西药组合物,其特征在于,包括以下重量分数的原料:醋酸氟轻松10-20份、氯雷他定片10-20份、维a酸1-5份、血塞通5-8份、红霉素5-8份、去痛片1-3份、蜂蜜10-15份、芦荟胶1-3份、咪康唑2-5份、菜籽油5-10份。
2.根据权利要求1所述的治疗烫伤的西药组合物,其特征在于,包括以下重量分数的原料:醋酸氟轻松15份、氯雷他定片13份、维a酸2份、血塞通6份、红霉素7份、去痛片2份、蜂蜜13份、芦荟胶2份、咪康唑3份、菜籽油8份。
3.一种如权利要求1-2任一所述的治疗烫伤的西药组合物的制备方法,其特征在于,具体步骤为:(1)首先将氯雷他定片、血塞通、去痛片研磨成粉末后混合,得到混合粉末A;(2)将醋酸氟轻松、维a酸、红霉素和咪康唑混合后得到膏状物质;(4)将上述膏状物质在40-60℃温度下干燥20-50min,然后磨成粉末B;(5)将粉末A和粉末B混合均匀,然后放入菜籽油中炸30-50s;(6)将油炸后的粉末与蜂蜜、芦荟胶混合,并搅拌均匀,即得膏状西药组合物。
4.根据权利要求3所述的治疗烫伤的西药组合物的制备方法,其特征在于,所述步骤(1)血塞通在研磨前先将糖衣去除。
5.根据权利要求3所述的治疗烫伤的西药组合物的制备方法,其特征在于,所述步骤(4)将上述膏状物质在50℃温度下干燥35min,然后磨成粉末B。
6.根据权利要求3所述的治疗烫伤的西药组合物的制备方法,其特征在于,所述步骤(5)将粉末A和粉末B混合均匀,然后放入菜籽油中炸45s。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611101764.5A CN106491914A (zh) | 2016-12-05 | 2016-12-05 | 一种治疗烫伤的西药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611101764.5A CN106491914A (zh) | 2016-12-05 | 2016-12-05 | 一种治疗烫伤的西药组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106491914A true CN106491914A (zh) | 2017-03-15 |
Family
ID=58329278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611101764.5A Pending CN106491914A (zh) | 2016-12-05 | 2016-12-05 | 一种治疗烫伤的西药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106491914A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107625832A (zh) * | 2017-09-27 | 2018-01-26 | 覃益祥 | 一种缓解烫伤的中药组合物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104984249A (zh) * | 2015-07-17 | 2015-10-21 | 曾德锋 | 用于治疗烫伤的组合物及其制备方法 |
CN105999213A (zh) * | 2016-06-15 | 2016-10-12 | 通江县光泰科技发展有限责任公司 | 一种大鲵皮人体皮肤修复膏剂的制备方法 |
-
2016
- 2016-12-05 CN CN201611101764.5A patent/CN106491914A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104984249A (zh) * | 2015-07-17 | 2015-10-21 | 曾德锋 | 用于治疗烫伤的组合物及其制备方法 |
CN105999213A (zh) * | 2016-06-15 | 2016-10-12 | 通江县光泰科技发展有限责任公司 | 一种大鲵皮人体皮肤修复膏剂的制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107625832A (zh) * | 2017-09-27 | 2018-01-26 | 覃益祥 | 一种缓解烫伤的中药组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014212561A1 (en) | Compositions and methods for treating surface wounds | |
CN108186711A (zh) | 促进伤口愈合的药物组合物 | |
CN101310748A (zh) | 一种治疗烧烫伤的软膏 | |
CN101837082B (zh) | 治疗烧伤的中药制剂 | |
CN1739719A (zh) | 一种治疗皮肤病的中药制剂 | |
CN111617189B (zh) | 一种治疗皮肤干燥皴裂的中药组合物 | |
CN101439114B (zh) | 一种治疗烧烫伤的中药及其制备方法 | |
CN105343332A (zh) | 茵陈虎杖复方药膏剂及其制备方法 | |
CN103585347B (zh) | 一种治疗烧烫伤的中药组合物及其制备方法 | |
CN105030620A (zh) | 一种保湿祛痘洗面奶及其制备方法 | |
CN106491914A (zh) | 一种治疗烫伤的西药组合物 | |
CN109602854B (zh) | 一种用于治疗烧烫伤的药膏及其制备方法 | |
CN105232606B (zh) | 一种用于痤疮治疗的外用药物组合物及其制备方法 | |
CN102274380A (zh) | 治疗烧、烫伤的外用药 | |
CN106511656A (zh) | 一种用于烫伤的西药组合物 | |
CN106692540A (zh) | 一种用于烫伤的药物组合物 | |
CN102846799A (zh) | 烧烫伤中药外用膏及其制备方法 | |
CN104147315A (zh) | 一种治疗烫烧伤的乳液药及其制备方法 | |
CN105168503B (zh) | 一种用于防治放射性皮炎的外用中药组合物及其制备方法 | |
CN105168091A (zh) | 一种祛红血丝面膜粉及其制备方法 | |
CN101036712A (zh) | 烫烧伤软膏 | |
CN109248217A (zh) | 一种治疗烧烫伤的膏剂及其制备方法 | |
CN104606340A (zh) | 一种纯天然中药修复润肤膏 | |
CN1089494A (zh) | 生肌愈皮膏 | |
CN109045204A (zh) | 一种治疗烧伤和烫伤的中药液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170315 |